Pyxis Oncology Pushes Monotherapy Data Update Into Fall
Pyxis secured approximately $50 million in upfront financing proceeds, which, together with existing cash, extended its cash runway into the second quarter of 2027, the company said.
Pyxis Oncology, Inc. (PYXS), a clinical-stage developer of treatments for difficult-to-treat cancers, moved its next MICVO monotherapy data update to the fall, shifting a milestone it had targeted for midyear in both its March and May updates. The company said fresh financing gave it greater flexibility to incorporate longer patient follow-up and planned analyses into its next clinical disclosures.
The timing change followed completion of target enrollment in the monotherapy dose expansion study during the first quarter. Pyxis expects the fall update to examine safety, tolerability, efficacy and initial durability among patients treated at or below a dose cap. The study involved patients with recurrent or metastatic head and neck squamous cell carcinoma receiving second-line or later treatment. Its two arms covered different prior-treatment histories, with target enrollment of approximately 20 patients in each arm.
The dosing question remained central to the planned disclosure. Pyxis implemented the cap for patients with higher body weight in December 2025. In May, the company said its goal was to maintain efficacy while improving safety and tolerability. Internal pharmacokinetic modeling indicated comparable expected drug exposure from dose capping and adjusted ideal bodyweight dosing, and the company prioritized the cap for operational simplicity and speed of implementation.
Earlier results provided the backdrop for that assessment. Preliminary monotherapy data shared in December 2025 showed a confirmed objective response rate of 46% among 13 efficacy-evaluable patients. Those results covered treatment using total body weight dosing. The forthcoming disclosure therefore focuses on a dosing approach introduced after those preliminary results, with the company planning detailed analyses of the cap’s impact rather than reporting a new efficacy result in the second-quarter announcement.
The financing changed the period Pyxis expects its resources to cover. The company now expects cash to fund operations into the second quarter of 2027, compared with the fourth quarter of 2026 projected in May. Interim Chief Executive Officer Tom Civik said the additional capital gave Pyxis greater flexibility to incorporate longer patient follow-up. The funds also provided room for data to mature following completion of enrollment.
Pyxis held $34.5 million in cash, cash equivalents, restricted cash and short-term investments at June 30. That balance included $10.0 million received ahead of the private placement’s July 2 completion. The transaction produced approximately $50 million in total upfront gross proceeds before fees and expenses; part of that amount was therefore already included in quarter-end liquidity.
The financing’s advertised maximum was not all cash received. The placement included warrants that could produce approximately $64 million in additional gross proceeds if exercised fully for cash. Those conditional proceeds accounted for the balance of the financing announced as totaling up to $114 million.
Second-quarter net loss widened to $25.3 million from $18.4 million a year earlier. The loss amounted to $0.40 a share. Pyxis recorded no milestone revenue during the quarter, while total operating expenses were $26.0 million. The private placement closed on July 2, but $10.0 million of its upfront proceeds had been received on June 30 and were already included in quarter-end liquidity.
General and administrative expenses increased to $9.9 million from $5.4 million, primarily because of higher severance costs and stock-based compensation. Research and development spending was $16.1 million. Pyxis attributed its lower research spending to reduced manufacturing costs, partly offset by higher clinical trial and preclinical study expenses.
The next clinical disclosure after monotherapy remains the combination program. Pyxis expects updated results for MICVO with Merck’s pembrolizumab in the fourth quarter, narrowing its earlier second-half timetable. That study remained in dose escalation across multiple doses in first-line recurrent or metastatic head and neck cancer, placing a second clinical update on the company’s calendar before year-end.
Stronger demand supports expansion as pricing diverges